BD (NYSE:BDX) today announced the introduction of the Elyra thulium fiber laser (TFL) system for treating kidney stones.

Becton Dickinson expects to achieve currency-neutral revenue growth in the low single-digit range for the current fiscal year ...

In early May 2026, Becton, Dickinson and Company reported higher quarterly sales of US$4.71 billion but swung to a net loss, raised its full-year adjusted earnings guidance, completed the divestiture ...

The Elyra TFL system is available in two versions, Elyra and Elyra Plus.

Let’s do a little imagining. Your brain is a city full of cell towers and neurons are the towers. Your thoughts, memories and ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

On February 5, 2025, Becton, Dickinson and Company (BD) announced plans to separate its Biosciences and Diagnostic Solutions business into an independent entity. The Biosciences and Diagnostic ...

Becton, Dickinson and Co. is increasing its U.S. manufacturing capacity for essential medical devices, including syringes, needles and IV catheters. As part of a $10 million investment in 2024, new ...

As the market for GLP-1 injections continues to grow, BD aims to ride that wave by providing drugmakers with its prefilled syringes. Biologic medications—including those blockbusters for diabetes and ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.